Arthritis Therapeutics Market
Arthritis Therapeutics Market Analysis by Type (Rheumatoid Arthritis, Osteoarthritis, Arthritis, Gout), By Drug Class, By Route of Administration, By Distribution Channel, By Region - Global Market Insights 2019 to 2027
Analysis of Arthritis Therapeutics Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Arthritis Therapeutics Market Outlook 2019 to 2027
It’s a common disorder that causes joint pain and It can extend to inflammation if not treated properly. Persistence of the same without treatment is likely to create difficulties in movement and walking. Each of these disease type causes distinct symptoms and may develop in women, men, and children. It’s the most common disorder present in the population across the U.S. as about 50 million adults manage some type of arthritis.
Global health data suggests that, the populace in North America and Europe are more conscious regarding arthritis, and actively partake in diagnosis than those residing in developing countries.
Sensing the success rate of arthritis therapeutics, manufacturers are allocating high budgets to fuel their research & development activities, which ensures the future availability of blockbuster drugs.
The recent time is, however, witnessing a shifting paradigm of patients’ reliance from pharmaceutical products towards biologics, as biologic therapies are reported to bring dramatic improvements in patients’ quality of life.
Furthermore, there are several biologic products in phase III clinical trials, which is indicative of strong commercial prospects for arthritis therapeutics manufacturers.
Weighing the impact of key influencers, a recent report published by Fact.MR infers that, the arthritis therapeutics market is estimated to grow 1.5X during the forecast period (2020 to 2027).
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What are impelling reasons behind the demand for therapeutics?
Around 100 different forms of arthritis exist in the world, with rheumatoid, osteoarthritis, psoriatic, and inflammatory arthritis being the most prevalent. Monocyte infiltration, inflammation, synovial swelling, pannus development, joint stiffness, and articular cartilage loss are all symptoms of arthritis that are present in all forms. There is currently no known cure for arthritis, and its specific cause is still unknown. In the management of arthritis, nonsteroidal anti-inflammatory medications (NSAIDs) and corticosteroids are frequently utilized.
The recent time is, however, witnessing a shifting paradigm of patients’ reliance on pharmaceutical products towards biologics, as biologic therapies are reported to bring dramatic improvements in patients’ quality of life.
Furthermore, there are several biologic products in phase III clinical trials, which is indicative of strong commercial prospects for manufacturers. Weighing the impact of key influencers, a recent report published by Fact.MR infers that the market is estimated to grow 1.5X during the forecast period (2020 to 2027).
What are factors that might deter the growth?
Enhanced drug prices to create hindrances in mass penetration
Advanced antibody therapeutics have been outperforming the sales of disease-modifying antirheumatic drugs (DMARD) in recent times, on account of their relatively high efficiency.
However, better outcomes offered by these drugs come at a price, a steep one indeed, which accommodates a range of US$ 1,000 to US$ 3,000 per month.
The price of the popular drug used for the treatment of arthritis - Humira - increased by 100% from US$ 19,000 a year in 2012 to US$ 38,000 a year in 2018, as per data presented by SSR Health.
This price rise is not limited to only Humira. Enbrel saw an 80% hike in its price since 2013, as reported by the Alliance of Community Health Plans. Given the long-term recommendation of these drugs to control arthritis, a perpetual increase in prices could shake the monthly budgets of patients, and, hence, divert their attention toward complementary and alternative therapies.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
How can Manufacturers Offset Challenges Associated with High Cost of Drugs?
High penetration of smartphones in parallel to low-cost of operation of distribution network is promising the growth of online pharmacies as a key distribution channel.
In the arthritis therapeutics market, where high cost concerns have been impeding sales prospects for players, targeting sales through online pharmacies can help offset the challenge through heavy deals and discounts offered by these channels.
In 2020, online pharmacies are projected to drive sales tantamount to a value of US$ 3.5 Bn, and the trend of online shopping driven by convenience will strengthen sales in future.
Currently, retail pharmacies account for 79% of total sales in the arthritis therapeutics market, as large chains and strong distribution network coupled with 24X7 accessibility is gaining prominence to this distribution channel. It is recommended for players in the arthritis therapeutics market to increase distribution-oriented partnerships with key retail partners to amplify their sales.
North America’s Lead Fuelled by High Availability of Drugs
The arthritis therapeutics market is more concentrated in developed regions such as North America and Europe as compared to other parts of the world.
Rigorous research & development initiatives undertaken by players concentrated in these regions are projected to diversify portfolios, strengthen the pipeline of drugs, and, in turn, boost the availability of drugs.
Recent addition of biologic and biosimilar in the arthritis therapeutics list, on the backdrop of patent expiration of blockbuster drugs, is witnessed in these regions.
In developing regions, increasing investments directed towards bringing progressive improvements in the healthcare industry are projected to promise strong growth for the arthritis therapeutics market in Asia Pacific.
In developed countries of Asia Pacific, such as Japan, New Zealand, and Australia, the adoption of biologic drugs is anticipated to remain high during the forecast period.
Top Companies Listed in Report:
- Novartis AG
- Eli Lilly and Company
- Amgen, Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Pfizer, Inc.
- AbbVie, Inc.
- Janssen Global Services, LLC (Johnson & Johnson)
- Hoffmann-La Roche Ltd
- Sanofi
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
What are the trends in this sector Organisations should not miss?
The preference for the parenteral route of administration will be 83% more than the topical and oral routes combined in 2020, on account of the high precision of dosage offered by this route, which leads to better patient outcomes.
Cost and recovery time, in turn, are turning out to be key determiners in the selection of route of administration.
Following this, increased availability of biosimilar products at competitive rates through parenteral routes is projected to retain a high preference for the injection of drugs during the forecast period.
On a relative note, patients’ proclivity for oral arthritis therapeutics is likely to remain moderate, as this route is preferred in cases wherein patients are required to follow a long-term course of medication.
Additionally, the introduction of topical NSAIDs for the treatment of joint pains will offer low-to-moderate stimulus to the topical route of administration in the market during the forecast period.
What strategic responses are expected from manufacturers?
E-Pharmacy to take along a swift uptake in the industry
The high penetration of smartphones in parallel with the low cost of operation of the distribution network is promising the growth of online pharmacies as a key distribution channel. With the quality assurance and speedy delivery of medicines, e-pharmacy is expected to gain growth with the fastest CAGR in the forecast period.
In the market, where high-cost concerns have been impeding sales prospects for players, targeting sales through online pharmacies can help offset the challenge through heavy deals and discounts offered by these channels. In 2020, online pharmacies are projected to drive sales tantamount to a value of US$ 3.5 Bn, and the trend of online shopping driven by convenience will strengthen sales in the future.
Currently, retail pharmacies account for 79% of total sales in the market, as large chains and strong distribution network coupled with 24X7 accessibility is gaining prominence to this distribution channel. It is recommended for players in the industry to increase distribution-oriented partnerships with key retail partners to amplify their sales.
Arthritis Therapeutics Market - Assessment of Key Segments
With an aim to offer granular level insights into the arthritis therapeutics market, authors of the report have segmented the landscape on the basis of type, drug class, route of administration, distribution channel, and region. This global research report also offers information regarding the incremental opportunity available in the arthritis therapeutics market during the forecast period. Key segments of the arthritis therapeutics market include:
-
By Type :
- Rheumatoid Arthritis
- Osteoarthritis
- Arthritis
- Gout
- Others
-
By Drug Class :
- TNF Inhibitors
- Interleukin Inhibitors
- NSAIDS
- Corticosteroids
- Xanthine Oxidase Inhibitors
- Others
-
By Route of Administration :
- Oral
- Parenteral
- Topical
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Table of Content
- 1. Preface
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Market
- 4. Market Overview
- 5. Key Insights
- 6. Global Market Analysis and Forecast, By Type
- 6.1. Rheumatoid Arthritis
- 6.2. Osteoarthritis
- 6.3. Psoriatic Arthritis
- 6.4. Gout
- 6.5. Others
- 7. Global Market Analysis and Forecast, By Drug Class
- 7.1. TNF Inhibitors
- 7.2. Interleukin Inhibitors
- 7.3. NSAIDs
- 7.4. Corticosteroids
- 7.5. Xanthine Oxidase Inhibitors
- 7.6. Others
- 8. Global Market Analysis and Forecast, By Route of Administration
- 8.1. Oral
- 8.2. Parenteral
- 8.3. Topical
- 9. Global Market Analysis and Forecast, By Distribution Channel
- 9.1. Hospital Pharmacies
- 9.2. Retail Pharmacies
- 9.3. Online Pharmacies
- 10. Global Market Analysis and Forecast, By Region
- 10.1. North America
- 10.2. Europe
- 10.3. Asia Pacific
- 10.4. Latin America
- 10.5. Middle East & Africa
- 11. North America Market Analysis and Forecast
- 12. Europe Market Analysis and Forecast
- 13. Asia Pacific Market Analysis and Forecast
- 14. Latin America Market Analysis and Forecast
- 15. Middle East & Africa Market Analysis and Forecast
- 16. Competition Landscape
- 16.1. Novartis AG
- 16.2. Eli Lilly and Company
- 16.3. Amgen, Inc.
- 16.4. Merck & Co., Inc.
- 16.5. Bristol-Myers Squibb Company
- 16.6. Pfizer, Inc.
- 16.7. AbbVie, Inc.
- 16.8. Janssen Global Services, LLC (Johnson & Johnson)
- 16.9. F. Hoffmann-La Roche Ltd
- 16.10. Sanofi
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Forecast, by Type, 2017 to 2027
Table 02: Global Market Value (US$ Mn) Forecast, by Drug Class, 2017 to 2027
Table 03: Global Market Value (US$ Mn) Forecast, by Route of Administration, 2017 to 2027
Table 04: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2017 to 2027
Table 05: Global Market Value (US$ Mn) Forecast, by Region, 2017 to 2027
Table 06: North America Value (US$ Mn) Forecast, by Type, 2017 to 2027
Table 07: North America Value (US$ Mn) Forecast, by Drug Class, 2017 to 2027
Table 08: North America Value (US$ Mn) Forecast, by Route of Administration,
Table 09: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2017 to 2027
Table 10: North America Market Value (US$ Mn) Forecast, By Country/Sub-region , 2017 to 2027
Table 11: Europe Value (US$ Mn) Forecast, by Type, 2017 to 2027
Table 12: Europe Value (US$ Mn) Forecast, by Drug Class, 2017 to 2027
Table 13: Europe Value (US$ Mn) Forecast, by Route of Administration, 2017 to 2027
Table 14: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2017 to 2027
Table 15: Europe Market Value (US$ Mn) Forecast, By Country/Sub-region, 2017 to 2027
Table 16: Asia Pacific Market Value (US$ Mn) Forecast, by Type, 2017 to 2027
Table 17: Asia Pacific Market Value (US$ Mn) Forecast, by Drug Class, 2017 to 2027
Table 18: Asia Pacific Market Value (US$ Mn) Forecast, by Route of Administration, 2017 to 2027
Table 19: Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2017 to 2027
Table 20: Asia Pacific Market Value (US$ Mn) Forecast, By Country/Sub-region, 2017 to 2027
Table 21: Latin America Value (US$ Mn) Forecast, by Type, 2017 to 2027
Table 22: Latin America Value (US$ Mn) Forecast, by Drug Class, 2017 to 2027
Table 23: Latin America Value (US$ Mn) Forecast, by Route of Administration, 2017 to 2027
Table 24: Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2017 to 2027
Table 25: Latin America Market Value (US$ Mn) Forecast, By Country/Sub-region, 2017 to 2027
Table 26: Middle East & Africa Value (US$ Mn) Forecast, by Type, 2017 to 2027
Table 27: Middle East & Africa Value (US$ Mn) Forecast, by Drug Class, 2017 to 2027
Table 28: Middle East & Africa Value (US$ Mn) Forecast, by Route of Administration, 2017 to 2027
Table 29: Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2017 to 2027
Table 30: Middle East & Africa Market Value (US$ Mn) Forecast, By Country/Sub-region, 2017 to 2027
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Snapshot
Figure 02: Global Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027
Figure 03: Global Market Value (US$ Mn) Forecast, 2017 to 2027
Figure 04: Global Market Value Share (%), by Type (2018)
Figure 05: Global Market Value Share (%), by Route of Administration (2018)
Figure 06: Global Market Value Share (%), by Drug Class (2018)
Figure 07: Global Market Value Share (%), by Distribution Channel (2018)
Figure 08: Global Market Value Share (%), by Region (2018)
Figure 09: Global Market Value Share Analysis, by Type, 2018 and 2027
Figure 10: Global Market Attractiveness, by Type, 2019 to 2027
Figure 11: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Rheumatoid Arthritis, 2017 to 2027
Figure 12: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Osteoarthritis, 2017 to 2027
Figure 13: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Psoriatic Arthritis, 2017 to 2027
Figure 14: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Gout, 2017 to 2027
Figure 15: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017 to 2027
Figure 16: Global Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 17: Global Market Attractiveness, by Drug Class, 2019 to 2027
Figure 18: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by TNF Inhibitors, 2017 to 2027
Figure 19: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Interleukin Inhibitors, 2017 to 2027
Figure 20: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by NSAIDs, 2017 to 2027
Figure 21: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2017 to 2027
Figure 22: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Xanthine Oxidase Inhibitors, 2017 to 2027
Figure 23: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017 to 2027
Figure 24: Global Market Value Share(%), by Route of Administration, 2018 and 2027
Figure 25: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2017 to 2027
Figure 26: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Parenteral, 2017 to 2027
Figure 27: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Topical, 2017 to 2027
Figure 28: Global Market Attractiveness, by Route of Administration, 2019 to 2027
Figure 29: Global Market Value Share (%), by Distribution Channel, 2018 and 2027
Figure 30: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2017 to 2027
Figure 31: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2017 to 2027
Figure 32: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2017 to 2027
Figure 33: Global Market Attractiveness, by Distribution Channel, 2019 to 2027
Figure 34: Global Market Value Share Analysis, by Region 2018 and 2027
Figure 35: Global Market Attractiveness, by Region, 2019 to 2027
Figure 36: North America Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017 to 2027
Figure 37: North America Market Value Share (%), by Type, 2018 and 2027
Figure 38: North America Market Attractiveness, by Type, 2019 to 2027
Figure 39: North America Market Value Share (%), by Drug Class, 2018 and 2027
Figure 40: North America Market Attractiveness, by Drug Class, 2019 to 2027
Figure 41: North America Market Value Share (%), by Route of Administration, 2018 and 2027
Figure 42: North America Market Attractiveness, by Route of Administration, 2019 to 2027
Figure 43: North America Market Value Share (%), by Distribution Channel, 2018 and 2027
Figure 44: North America Market Attractiveness, by Distribution Channel, 2019 to 2027
Figure 45 : North America Market Value Share (%), By Country/Sub-region , 2018 and 2027
Figure 46: North America Market Attractiveness, By Country/Sub-region , 2019 to 2027
Figure 47: Europe Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017 to 2027
Figure 48: Europe Market Value Share (%), by Type, 2018 and 2027
Figure 49: Europe Market Attractiveness, by Type, 2019 to 2027
Figure 50: Europe Market Value Share (%), by Drug Class, 2018 and 2027
Figure 51: Europe Market Attractiveness, by Drug Class, 2019 to 2027
Figure 52: Europe Market Value Share (%), by Route of Administration, 2018 and 2027
Figure 53: Europe Market Attractiveness, by Route of Administration, 2019 to 2027
Figure 54: Europe Market Value Share (%), by Distribution Channel, 2018 and 2027
Figure 55: Europe Market Attractiveness, by Distribution Channel, 2019 to 2027
Figure 56: Europe Market Value Share (%), By Country/Sub-region /Sub-region, 2018 and 2027
Figure 57: Europe Market Attractiveness, By Country/Sub-region /Sub-region, 2019 to 2027
Figure 58: Asia Pacific Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017 to 2027
Figure 59: Asia Pacific Market Value Share (%), by Type, 2018 and 2027
Figure 60: Asia Pacific Market Attractiveness, by Type, 2019 to 2027
Figure 61: Asia Pacific Market Value Share (%), by Drug Class, 2018 and 2027
Figure 62: Asia Pacific Market Attractiveness, by Drug Class, 2019 to 2027
Figure 63: Asia Pacific Market Value Share (%), by Route of Administration, 2018 and 2027
Figure 64: Asia Pacific Market Attractiveness, by Route of Administration, 2019 to 2027
Figure 65: Asia Pacific Market Value Share (%), by Distribution Channel, 2018 and 2027
Figure 66: Asia Pacific Market Attractiveness, by Distribution Channel, 2019 to 2027
Figure 67 : Asia Pacific Market Value Share (%), By Country/Sub-region /Sub-region, 2018 and 2027
Figure 68: Asia Pacific Market Attractiveness, By Country/Sub-region /Sub-region, 2019 to 2027
Figure 69: Latin America Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017 to 2027
Figure 70: Latin America Market Value Share (%), by Type, 2018 and 2027
Figure 71: Latin America Market Attractiveness, by Type, 2019 to 2027
Figure 72: Latin America Market Value Share (%), by Drug Class, 2018 and 2027
Figure 73: Latin America Market Attractiveness, by Drug Class, 2019 to 2027
Figure 74: Latin America Market Value Share (%), by Route of Administration, 2018 and 2027
Figure 75: Latin America Market Attractiveness, by Route of Administration, 2019 to 2027
Figure 76: Latin America Market Value Share (%), by Distribution Channel, 2018 and 2027
Figure 77: Latin America Market Attractiveness, by Distribution Channel, 2019 to 2027
Figure 78 : Latin America Market Value Share (%), By Country/Sub-region /Sub-region, 2018 and 2027
Figure 79: Latin America Market Attractiveness, By Country/Sub-region /Sub-region, 2019 to 2027
Figure 80: Middle East & Africa Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017 to 2027
Figure 81: Middle East & Africa Market Value Share (%), by Type, 2018 and 2027
Figure 82: Middle East & Africa Market Attractiveness, by Type, 2019 to 2027
Figure 83: Middle East & Africa Market Value Share (%), by Drug Class, 2018 and 2027
Figure 84: Middle East & Africa Market Attractiveness, by Drug Class, 2019 to 2027
Figure 85: Middle East & Africa Market Value Share (%), by Route of Administration, 2018 and 2027
Figure 86: Middle East & Africa Market Attractiveness, by Route of Administration, 2019 to 2027
Figure 87: Middle East & Africa Market Value Share (%), by Distribution Channel, 2018 and 2027
Figure 88: Middle East & Africa Market Attractiveness, by Distribution Channel, 2019 to 2027
Figure 89: Middle East & Africa Market Value Share (%), By Country/Sub-region /Sub-region, 2018 and 2027
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
Where will companies get maximum growth potential?
North America and Europe are expected to remain the dominant regions in this market.
What are the segments covered in the arthritis therapeutics market?
In the arthritis therapeutics market, authors of the report have segmented the landscape on the basis of type, drug class, route of administration, distribution channel, and region.
What is the growth rate of the global market?
The arthritis therapeutics market is estimated to grow 1.5x during the forecast period (2020 - 2027).
Which route of administration is widely preferred?
The preference for the parenteral route of administration will be 83% more than the topical and oral routes combined in 2020.
Arthritis Therapeutics Market